H.R. 8857

Summary

H.R. 8857, the Next GEN Act of 2026, was introduced in the House on May 15, 2026 by Rep. Joseph Morelle (D) with 4 co-sponsors. It was referred to Energy And Commerce, and last saw action on May 15, 2026: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Record

Text

H.R. 8857 has 4 co-sponsors.

119 HR 8857 IH: Next Generation Medicines Act of 2026
 U.S. House of Representatives
 2026-05-15
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  2d Session  H. R. 8857  IN THE HOUSE OF REPRESENTATIVES   May 15, 2026   Mr. Morelle  (for himself,  Mr. Gottheimer ,  Mr. Pfluger , and  Mr. Kean ) introduced the following bill; which was referred to the  Committee on Energy and Commerce , and in addition to the Committee on  Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned   A BILL
To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
1.
Short title
This Act may be cited as the   Next Generation Medicines Act of 2026   or the   Next GEN Act of 2026  .
2.
Adjusting rules for engineered cyclic peptides under Drug Price Negotiation Program
(a)
In general
Section 1192(e) of the Social Security Act ( 42 U.S.C. 1320f–1(e) ) is amended—
(1)
in paragraph (1)(A)(ii), by inserting  (or, in the case of an engineered cyclic peptide (as defined in paragraph (5)), 11 years)  after  7 years ; and
(2)
by adding at the end the following new paragraph:
(5)
Engineered cyclic peptide defined
In this subsection, the term  engineered cyclic peptide  means a polymer that—
(A)
is composed principally of amino acids;
(B)
contains not less than 1 cyclic structure produced through head-to-tail cyclization, head-to-side-chain cyclization, side-chain-to-tail cyclization, or side-chain-to-side-chain cyclization;
(C)
contains not more than 40 amino acids;
(D)
was identified for development using a genetically encoded library screening method;
(E)
is not naturally derived; and
(F)
is orally administered, inhaled, or otherwise self-administered.
 .
(b)
Effective date
The amendments made by this section shall apply with respect to lists published under section 1192(a) of the Social Security Act ( 42 U.S.C. 1320f–1(a) ) on or after the date of the enactment of this section.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.

Sponsors

Rep. Joseph Morelle (D) sponsors H.R. 8857, and 4 members have co-sponsored it, 3 of them from the day it was introduced.

Joseph Morelle

Rep. · D–NY-25 · Sponsor

Introduced May 15, 2026

Josh Gottheimer

Rep. · D–NJ-5 · Co-sponsor

Joined May 15, 2026 · Original

Thomas Kean

Rep. · R–NJ-7 · Co-sponsor

Joined May 15, 2026 · Original

August Pfluger

Rep. · R–TX-11 · Co-sponsor

Joined May 15, 2026 · Original

Donald Davis

Rep. · D–NC-1 · Co-sponsor

Joined Aug 27, 2026

Show 5 of 5 rows

PreviousNext

Committees

H.R. 8857 went before 2 committees: Ways and Means and Energy and Commerce.

Ways and Means

Ways and Means

Referred To · May 15, 2026 · 1,160 Bills

Energy and Commerce

Energy and Commerce

Referred To · May 15, 2026 · 1,636 Bills

Actions

H.R. 8857 has taken 2 actions since May 15, 2026.

Votes

H.R. 8857 has not gone to a roll call.

Titles

H.R. 8857 goes by 4 titles, 2 of them short titles.

• Next GEN Act of 2026 — Display Title
• To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program. — Official Title as Introduced
• Next GEN Act of 2026 — Short Title(s) as Introduced
• Next Generation Medicines Act of 2026 — Short Title(s) as Introduced

Lobbying

1 client hired 1 firm and 4 registered lobbyists who named H.R. 8857 in 1 quarterly filing, 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Medicare/Medicaid, Trade (domestic/foreign).

Clients

Who paid to be heard, by how many filings named the bill.

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

Classification

The Congressional Research Service files H.R. 8857 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 8857’s is Health.

Constitutional authority

The clause the sponsor cites as Congress’s power to enact H.R. 8857, as entered in the Congressional Record.

[Congressional Record Volume 172, Number 83 (Friday, May 15, 2026)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. MORELLE:H.R. 8857.Congress has the power to enact this legislation pursuantto the following:Clause 18 Section 8 Article 1[Page H3551]

Source: congress.gov · legiscan.com